RT Journal Article
SR Electronic
T1 Exposure to SARS-CoV-2 within the household is associated with greater symptom severity and stronger antibody responses in a community-based sample of seropositive adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.11.21253421
DO 10.1101/2021.03.11.21253421
A1 Schrock, Joshua M.
A1 Ryan, Daniel T.
A1 Saber, Rana
A1 Benbow, Nanette
A1 Vaught, Lauren A.
A1 Reiser, Nina
A1 Velez, Matthew P.
A1 Hsieh, Ryan
A1 Newcomb, Michael
A1 Demonbreun, Alexis R.
A1 Mustanski, Brian
A1 McNally, Elizabeth M.
A1 D’Aquila, Richard
A1 McDade, Thomas W.
YR 2021
UL http://medrxiv.org/content/early/2021/03/12/2021.03.11.21253421.abstract
AB Magnitude of SARS-CoV-2 virus exposure may contribute to symptom severity. In a sample of seropositive adults (n=1101), we found that individuals who lived with a known COVID-19 case exhibited greater symptom severity and IgG concentrations compared to individuals who were seropositive but did not live with a known case (P<0.0001).Competing Interest StatementDr. McDade reports that he has a financial interest in EnMed Microanalytics, a company that conducts lab tests using DBS samples. Dr. D'Aquila reports personal fees from Abbvie, outside the submitted work. Dr. McNally reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from Cytokinetics, personal fees from Pfizer, personal fees from Tenaya Therapeutics, personal fees from 4D Molecular Therapeutics, outside the submitted work.Funding StatementThis material is based upon work supported by the National Science Foundation under Grant No. 2035114. Additional support was provided by the Northwestern University Office of Research, the Northwestern University Clinical and Translational Sciences Institute (NIH UL1TR001422), and a generous gift from Dr. Andrew Senyei and Noni Senyei. The funding sources had no role in the study design, data collection, analysis, interpretation, or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All samples were de-identified and all research activities were implemented under protocols approved by the institutional review board at Northwestern University (#STU00212457 and #STU00212472).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request from the corresponding author subject to an approved data sharing agreement to protect participant confidentiality.